Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:GALT's Cash-to-Debt is ranked higher than
99% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. NAS:GALT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:GALT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.41  Med: No Debt Max: No Debt
Current: No Debt
0.41
No Debt
Piotroski F-Score: 3
Altman Z-Score: 1.60
WACC vs ROIC
24.78%
399.85%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE % -529.22
NAS:GALT's ROE % is ranked lower than
99% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. NAS:GALT: -529.22 )
Ranked among companies with meaningful ROE % only.
NAS:GALT' s ROE % Range Over the Past 10 Years
Min: -1658.88  Med: -149.59 Max: -107.68
Current: -529.22
-1658.88
-107.68
ROA % -203.15
NAS:GALT's ROA % is ranked lower than
98% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. NAS:GALT: -203.15 )
Ranked among companies with meaningful ROA % only.
NAS:GALT' s ROA % Range Over the Past 10 Years
Min: -1309.12  Med: -141.18 Max: -71.42
Current: -203.15
-1309.12
-71.42
3-Year EBITDA Growth Rate 13.50
NAS:GALT's 3-Year EBITDA Growth Rate is ranked higher than
62% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. NAS:GALT: 13.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:GALT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.7  Med: 1.95 Max: 22.4
Current: 13.5
-20.7
22.4
3-Year EPS without NRI Growth Rate 14.40
NAS:GALT's 3-Year EPS without NRI Growth Rate is ranked higher than
60% of the 663 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. NAS:GALT: 14.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:GALT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -36.2  Med: 7.35 Max: 33.7
Current: 14.4
-36.2
33.7
GuruFocus has detected 1 Warning Sign with Galectin Therapeutics Inc NAS:GALT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:GALT's 30-Y Financials

Financials (Next Earnings Date: 2018-11-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

GALT Guru Trades in

Q1 2017

GALT Guru Trades in Q1 2017

Charles Brandes 28,500 sh (New)
» More
Q2 2017

GALT Guru Trades in Q2 2017

Charles Brandes 28,500 sh (unchged)
» More
Q3 2017

GALT Guru Trades in Q3 2017

Charles Brandes Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:GALT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2017-09-30 Sold Out $1.67 - $2.48 $ 3.7789%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Galectin Therapeutics Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:ROCO:6535, TSXV:ICC, DHA:ORIONPHARM, BOM:590006, ROCO:6620, XCNQ:TER, NAS:EYPT, TSXV:WMD, XKRX:220100, LSE:SPH, ASX:EXL, OTCPK:OPTI, BOM:531146, XKRX:009300, TSX:IN, NAS:ADMP, MIL:PHN, ROCO:6496, ROCO:6472, TSXV:RX » details
Traded in other countries:PHPN.Germany,
Headquarter Location:USA
Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.

Galectin Therapeutics Inc is a biotechnology company. The company is focused on discovery and development. It is engaged in galectin science and drug development to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function. Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis.

Ratios

vs
industry
vs
history
PB Ratio 171.36
GALT's PB Ratio is ranked lower than
99.99% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. GALT: 171.36 )
Ranked among companies with meaningful PB Ratio only.
GALT' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 457.5
Current: 171.36
0
457.5
EV-to-EBIT -10.28
GALT's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. GALT: -10.28 )
Ranked among companies with meaningful EV-to-EBIT only.
GALT' s EV-to-EBIT Range Over the Past 10 Years
Min: -23.41  Med: 0 Max: 0
Current: -10.28
-23.41
0
EV-to-EBITDA -10.28
GALT's EV-to-EBITDA is ranked lower than
99.99% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. GALT: -10.28 )
Ranked among companies with meaningful EV-to-EBITDA only.
GALT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -23.41  Med: 0 Max: 0
Current: -10.28
-23.41
0
Current Ratio 7.69
GALT's Current Ratio is ranked lower than
57% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. GALT: 7.69 )
Ranked among companies with meaningful Current Ratio only.
GALT' s Current Ratio Range Over the Past 10 Years
Min: 0.2  Med: 3.71 Max: 23.21
Current: 7.69
0.2
23.21
Quick Ratio 7.69
GALT's Quick Ratio is ranked higher than
53% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. GALT: 7.69 )
Ranked among companies with meaningful Quick Ratio only.
GALT' s Quick Ratio Range Over the Past 10 Years
Min: 0.2  Med: 3.71 Max: 23.21
Current: 7.69
0.2
23.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.10
GALT's 3-Year Average Share Buyback Ratio is ranked lower than
74% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. GALT: -17.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GALT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.1  Med: -18.65 Max: -10.6
Current: -17.1
-26.1
-10.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 19.53
GALT's Price-to-Net-Cash is ranked lower than
99.99% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.41 vs. GALT: 19.53 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GALT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 12.28 Max: 210
Current: 19.53
0
210
Price-to-Net-Current-Asset-Value 185.50
GALT's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. GALT: 185.50 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GALT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 12.4 Max: 732
Current: 185.5
0
732
Price-to-Tangible-Book 188.50
GALT's Price-to-Tangible-Book is ranked lower than
99.99% of the 749 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. GALT: 188.50 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GALT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.71  Med: 12.3 Max: 430
Current: 188.5
2.71
430
Earnings Yield (Greenblatt) % -9.73
GALT's Earnings Yield (Greenblatt) % is ranked lower than
82% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. GALT: -9.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GALT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -25770.33  Med: 0 Max: 4520.18
Current: -9.73
-25770.33
4520.18

More Statistics

EPS (TTM) $ -0.43
Beta3.65
Volatility92.11%
52-Week Range $1.28 - 9.49
Shares Outstanding (Mil)40.91

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.38 -0.81 -0.87
EPS without NRI ($) -0.38 -0.81 -0.87
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}